# A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Study · id `cardio:ct-nct06742723` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06742723](<https://clinicaltrials.gov/study/NCT06742723>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06742723

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5000 participants.

## Technical summary

Registry record NCT06742723. Randomized; quadruple masking; primary purpose treatment. Start 2025-03-03 (actual); primary completion 2029-12-18 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 5000 participants (planned count; ClinicalTrials.gov record NCT06742723, source copy `cardio:ctgov-nct06742723-2026-11-06`, retrieved 2026-11-18)
- Started: 2025-03-03 (actual) (ClinicalTrials.gov record NCT06742723, source copy `cardio:ctgov-nct06742723-2026-11-06`, retrieved 2026-11-18)
- Primary completion: 2029-12-18 (anticipated) (ClinicalTrials.gov record NCT06742723, source copy `cardio:ctgov-nct06742723-2026-11-06`, retrieved 2026-11-18)
- Completion: 2029-12-18 (anticipated) (ClinicalTrials.gov record NCT06742723, source copy `cardio:ctgov-nct06742723-2026-11-06`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; Egypt; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Peru; Philippines; Poland; Romania; Saudi Arabia; Serbia; Singapore; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom; Vietnam (ClinicalTrials.gov record NCT06742723, source copy `cardio:ctgov-nct06742723-2026-11-06`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06742723-2026-11-06`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
- Acronym: BaxDuo-Pacific
- Condition: Chronic Kidney Disease and Hypertension
- Intervention (Drug): Baxdrostat/dapagliflozin
- Intervention (Drug): Placebo/dapagliflozin
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 49116b8484dd170e2f418d7105430432d4cd3d0047666f50a74268c901f3ef00
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
